Skip to main content
PHARMACOLOGY UPDATE

Caplacizumab-yhdp for Injection (Cablivi)

Caplacizumab-yhdp is indicated for the treatment of acquired thrombotic thrombocytopenic purpura in combination with plasma exchange and immunosuppressive therapy.